Press
Reports about InhalPlus and our technology, our press releases and information for journalists.
Media coverage
2026
VentureCapital Magazin 07/2026, special edition „Start-up 2027“ · in German
Case study: from the doctoral project to the spin-off, laboratory results and the planned clinical study.
28 October 2026 · Schaumburger Nachrichten, page 11 · print, in German
Jeder Atemzug zählt
Regional report on co-founder Dr. Gerhard Pohlmann, the development of the bypass system and the investment by NBank Capital.
26 October 2026 · Niedersachsen.next · in German
Report on the pre-seed investment by NBank Capital.
23 October 2026 · VC Magazin · in German
Deal report on the investment by NBank Capital.
22 October 2026 · transkript · in German
Life sciences magazine on the investment, the planned clinical study and market entry.
20 October 2026 · startupvalley.news · in German
Report on the investment by NBank Capital in the Fraunhofer spin-off.
20 October 2026 · NBank · in German
Press release by NBank on the investment of NBank Capital.
October 2026 · hannoverimpuls · in English and German
The economic development agency of the Hannover Region on the investment by NBank Capital.
6 October 2026 · bionity · in English
Report on the founding of InhalPlus GmbH.
5 October 2026 · Fraunhofer ITEM · in English and German
Press release by Fraunhofer ITEM on the founding of InhalPlus GmbH as a spin-off. German version
5 October 2026 · MT-Dialog · in German
Report on the founding and the planned proof-of-concept study.
5 October 2026 · Beatmungspflegeportal · in German
Report for respiratory care professionals on the founding of InhalPlus.
2025
7 July 2025 · Plattform Life Sciences · in German
Case study on the technology, the team and the path to the clinic.
May 2025 · Techniker Krankenkasse · in German
Interview with Dr. Felix Carl Wiegandt on networks, pitching and everyday life as a founder.
2024
3 December 2024 · Fraunhofer ITEM · in English
Funding from the Institute for Biomedical Translation (IBT) Lower Saxony for the clinical proof-of-concept study, then still under the project name Inhale+.
27 September 2024 · Fraunhofer · in English
Fraunhofer portrait of the founder and the planned spin-off, then still under the name Inhale+.
Issue 2/2024 · mt|medizintechnik, pages 36 to 38 · print, in German
Paradigmenwechsel als Ziel: Neue Generation der inhalativen Therapie Frühgeborener
Technical article by Dr. Felix Carl Wiegandt, Dr. Gerhard Pohlmann and Dr. Ute Urban on the challenges of inhalation therapy in preterm infants.
Press releases
20 October 2026 · InhalPlus
Press release with PDF downloads in English and German and press photos with captions and credits.
5 October 2026 · InhalPlus
News on the founding of InhalPlus GmbH with links to the press release by Fraunhofer ITEM.
All news: News
Press material
Press photos with captions and credits as well as our latest press release as a PDF in English and German are available with the press release of 20 October 2026. For further material, please contact us.
About InhalPlus
InhalPlus GmbH, based in Hannover, Germany, is developing a patented platform for inhaled drug delivery in patients receiving respiratory support. Its first application is premature infants on non-invasive respiratory support. The company was founded in August 2026 as a spin-off from Fraunhofer ITEM.
Media contact
InhalPlus GmbH
Dr. Felix Carl Wiegandt, CEO
Fichtestr. 37, 30625 Hannover, Germany
Phone +49 151 68423003
felix.wiegandt@inhalplus.com